SCHMID Group reports Q1 order intake of €13.6M, reaffirms 2026 guidance

SCHMID reported preliminary Q1 2026 revenue of €18.2 million and order intake of €13.6 million, while reaffirming full-year guidance for revenue above €100 million, Adjusted EBITDA margin above 12%, and order intake of about €114 million. The company also disclosed conversion notices for $12 million of convertible notes into 2,197,898 new shares, and set-off agreements to offset €30.75 million of liabilities subject to shareholder approval. Recent orders tied to HDI multilayer equipment and panel-level packaging for AI/high-performance computing applications underscore continued demand, though the equity dilution and preliminary nature of results temper the bullishness.

Analysis

The market is starting to value SHMD less like a cyclical equipment vendor and more like a financing story with an operating business attached. The combination of a visible order book, a re-affirmed year target, and incremental AI/HPC exposure helps support the multiple, but the bigger second-order effect is dilution: the converted notes and the pending liability offsets can materially expand equity supply before fundamentals have fully scaled. In small-cap industrials, that usually caps upside until the market can see a clean post-dilution earnings power number.

The next catalyst is not the quarterly print itself; it is the shareholder vote and the pricing mechanics on the liability set-off. If the shares stay elevated into the VWAP window, management effectively raises equity at a strong valuation and can de-risk the balance sheet without a cash outflow. If the stock weakens into the reference period, the dilution math becomes more punitive and could trigger a fast re-rate lower, especially because the equity has already run sharply and is vulnerable to mean reversion once the financing overhang dominates the story.

The contrarian read is that consensus may be underestimating how much of the current optimism is already embedded in a stock that has doubled in a year. The AI/HPC narrative is real, but in this name it mainly matters if it converts into larger, repeatable orders that extend beyond one-off equipment deliveries; otherwise, it remains a valuation overlay rather than an earnings engine. The cleanest expression is that the fundamental setup is positive, but the trade is now about sequencing: operations first, dilution second, upside only if both land in the right order.

Key Decisions for Investors

• Avoid initiating fresh outright longs into the shareholder-approval/VWAP window; dilution math is likely to dominate near-term price action, and the risk/reward is poor after a 6-month rerating.
• For existing holders, sell covered calls against a 4-8 week horizon to monetize elevated volatility while the market prices the financing overhang; use strikes 10-15% above spot to retain upside if the May 15 update surprises positively.
• Speculative short: fade strength post-approval with a tactical short or put spread if the stock trades above the implied post-dilution value; target a 1:2 risk/reward over 2-6 weeks, with the thesis invalidated if order intake visibly inflects above guidance pace.
• Relative value: pair long a higher-quality AI/HPC capex beneficiary with recurring demand against SHMD into earnings, because SHMD’s upside is more dependent on one-off equipment wins and balance-sheet optics than durable end-market penetration.
• Watch the May 15 earnings call for evidence of conversion from inquiry to backlog in China; if management can show accelerating order book turnover, consider a re-entry only after dilution clears and the new share count is fully reflected.